Gujarat Inject (Kerala) Q4 revenue zooms 19x to ₹30.7 cr
Full-year FY26 revenue nearly doubles to ₹36.3 crore; net profit turns positive. Capital work-in-progress of ₹20.8 crore signals ongoing expansion.
— 8 earlier stories on Gujarat Inject (Kerala) Ltd. →What's new
- Q4 revenue surged to ₹30.7 cr from ₹1.6 cr in Q3 and ₹4.2 cr a year ago.
- Full-year FY26 revenue nearly doubled to ₹36.3 cr.
- Net profit for Q4 at ₹1.64 cr vs ₹0.038 cr in Q3; CWIP at ₹20.8 cr.
Why this matters
The Q4 numbers represent a dramatic turnaround for a nano-cap that was essentially dormant. The ₹20.8 cr in capital work-in-progress suggests management is betting on continuation, but the quality and durability of the revenue spike remain open questions.
What we're watching
- Whether Q4 revenue momentum sustains in FY27.
- Details on the source of the revenue jump.
- Any management commentary on the expansion plans.
The full read
Gujarat Inject (Kerala) reported a stunning Q4 FY26, with revenue jumping to ₹30.7 crore from just ₹1.6 crore in the previous quarter and ₹4.2 crore a year ago. Full-year FY26 revenue nearly doubled to ₹36.3 crore, meaning Q4 alone accounted for 85% of the full year. Net profit turned positive at ₹1.64 crore versus near-zero in Q3. The balance sheet also shows ₹20.8 crore in capital work-in-progress, pointing to ongoing capacity expansion. For a nano-cap that was barely generating revenue quarters ago, this is a material inflection—if it can be sustained. The open question is whether this reflects a one-off contract or the start of a new growth trajectory.
Gujarat Inject (Kerala) Ltd.
Latest quarter · Jun 2026
Strength & growth
Story so far
All notes on GUJINJEC →- 20 May 2026 · 7:01 PM IST Gujarat Inject (Kerala) Q4 revenue zooms 19x to ₹30.7 cr
- 7d ago Gujarat Inject Q1 net profit rises to ₹1.25 crore on solar trading
- 7d ago Gujarat Inject Q1 net profit jumps to ₹125.16 lakh on solar trading
- 7d ago Gujarat Inject Q1 net profit jumps to ₹125.16 lakh on solar module trading
- 16d ago Gujarat Inject fills top post after chairman's death, but new MD is from plastics